[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc announced the purchase and cancellation of 1,369,903 ordinary shares under the second tranche of its share buyback programme. The trades were executed on the London Stock Exchange/CBOE (UK)/CXE on 22 August 2025 and a full breakdown of individual trades is linked in the release. After settlement, the company's registered share capital is 8,969,326,205 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares, leaving 8,965,446,000 ordinary shares with voting rights. The announcement clarifies where the trade details and the announcement are available online.

Positive

• Completed buyback tranche: 1,369,903 shares purchased and cancelled under the announced programme
• Updated capital disclosure: Clear post-settlement totals: 8,969,326,205 registered shares; 3,880,205 treasury; 8,965,446,000 voting shares
• Regulatory transparency: Individual trade breakdown provided and announcement posted on company website

Negative

• None.

Insights

Securities Analyst

TL;DR: A completed tranche of the buyback reduces the share count slightly, modestly increasing shareholder pro rata ownership.

The buyback of 1,369,903 shares is a straightforward execution under an existing programme. The reduction in issued shares and the updated count of voting shares are explicit and allow shareholders to recalculate ownership thresholds for disclosure purposes. The transaction size relative to total shares outstanding is small and the filing provides the required trade breakdown link consistent with market rules.

Corporate Governance Expert

TL;DR: Corporate actions properly disclosed; provides clarity on voting share count for disclosure rule compliance.

The Form 6-K discloses the cancellation and post-settlement share capital and treasury holdings, which is important for transparency and for shareholders assessing notification obligations under FCA rules. The filing references the Market Abuse Regulation disclosure and makes trade details available, aligning with regulatory expectations for share buyback reporting.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	26 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

26 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,369,903 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	22 August 2025	22 August 2025	22 August 2025
Number of Shares purchased:	1,369,903	-	-
Highest price paid per Share (p):	368.0000	-	-
Lowest price paid per Share (p):	364.2000	-	-
Volume weighted average price paid per Share (p):	366.7394	-	-

Following the settlement of the above, the Company's registered share capital is 8,969,326,205 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,965,446,000 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/5079W_1-2025-8-22.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 26, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

How many shares did Haleon (HLN) buy back on 22 August 2025?

Haleon bought and cancelled 1,369,903 ordinary shares executed on 22 August 2025.

What is Haleon's post-settlement registered share capital and voting shares?

Registered share capital is 8,969,326,205 ordinary shares of £0.01 each, with 8,965,446,000 ordinary shares carrying voting rights.

Where can I find the full breakdown of the individual trades for Haleon's buyback?

A full breakdown is available via the provided London Stock Exchange link: http://www.rns-pdf.londonstockexchange.com/rns/5079W_1-2025-8-22.pdf and on www.haleon.com/investors.

Are the repurchased shares being held in treasury or cancelled?

The announcement states the purchased shares were for cancellation under the second tranche of the buyback programme.

Does the filing include compliance references for the trade disclosure?

Yes, it references Article 5(1)(b) of Regulation (EU) No 596/2014 as applied in the UK (Market Abuse Regulation) for the trade breakdown disclosure.